Tumor cell detection in the bone marrow of DCIS patients is not associated with routine clinicopathological features
Introduction: In invasive breast cancer, the detection of disseminated tumor cells (DTCs) in the bone marrow (BM) is associated with larger tumor size, axillary lymph node involvement, estrogen (ER) and progesterone (PR) receptor negativity and human epidermal growth factor receptor 2 (HER2) positivity as well as aggressive molecular subtype (non-luminal). In patients with ductal carcinoma in situ (DCIS) any such association has yet to be shown.
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - Category: OBGYN Authors: Vincent Walter, Florin-Andrei Taran, Markus Wallwiener, Sara Brucker, Andreas Hartkopf Tags: Session 30 – Oncology: Breast Source Type: research
More News: Biology | Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | Carcinoma in Situ | DCIS (Ductal Carcinoma in Situ) | Ductal Carcinoma | HER2 | Molecular Biology | OBGYN